Article
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
The Lancet. Oncology - 1 Jan 2022
Fakih Marwan G, Kopetz Scott, Kuboki Yasutoshi, Kim Tae Won, Munster Pamela N, Krauss John C, Falchook Gerald S, Han Sae-Won, Heinemann Volker, Muro Kei, Strickler John H, Hong David S, Denlinger Crystal S, Girotto Gustavo, Lee Myung-Ah, Henary Haby, Tran Qui, Park Joseph K, Ngarmchamnanrith Gataree, Prenen Hans, Price Timothy J
Abstract excerpt
BACKGROUND: Sotorasib, a specific, irreversible KRASG12C protein inhibitor, has shown monotherapy clinical activity in KRASG12C-mutated solid tumours, including colorectal cancer, in the CodeBreaK100 phase 1 trial. We aimed to investigate the activity and safety of sotorasib in phase 2 of the trial. METHODS: In this single-arm, phase 2 trial, adult patients with KRASG12C-mutated advanced solid tumours were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.